rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2016-219-226rsp-2221Research ArticleОБЗОРREVIEWНовые оральные антикоагулянты в терапии антифосфолипидного синдромаNEW ORAL ANTICOAGULANTS IN THE THERAPY OF ANTIPHOSPHOLIPID SYNDROMEСатыбалдыеваМ. А.SatybaldyevaM. A.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522 

malabeth@rambler.ruРешетнякТ. М.ReshetnyakT. M.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522 

ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, МоскваРоссияV.A. Nasonova Research Institute of Rheumatology, MoscowRussian Federation201619072016542219226Copyright © Сатыбалдыева М.А., Решетняк Т.М., 20162016Сатыбалдыева М.А., Решетняк Т.М.Satybaldyeva M.A., Reshetnyak T.M.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2221

Основным препаратом из группы антикоагулянтов, применяемым для лечения антифосфолипидного синдрома (АФС), является антагонист витамина К варфарин. Однако у него имеется ряд недостатков, в особенности для пациентов, которым требуется длительная, а зачастую и пожизненная профилактика тромбозов. В последнее время были синтезированы новые пероральные антикоагулянты, такие как дабигатрана этексилат (Pradaxa®), ривароксабан (Xarelto®), апиксабан (Eliquis) и др. В отличие от варфарина, они применяются в фиксированных дозах, не требуют рутинного мониторинга, соблюдения диеты, взаимодействуют лишь с небольшим количеством препаратов. Новые пероральные антикоагулянты одобрены для применения по нескольким показаниям, но данные проведенных исследований не применимы для пациентов с АФС. Ожидается, что применение этих препаратов позволит улучшить качество жизни пациентов с АФС. 

The vitamin K antagonist warfarin is an essential medicine from a group of anticoagulants, which is used to treat antiphospholipid syndrome (APS). However, it has a number of disadvantages especially in patients who need longterm and frequently lifetime prevention of thromboses. New oral anticoagulants, such as dabigatran etexilate (Pradaxa®), rivaroxaban (Xarelto®), apixaban (Eliquis) and others, have been recently synthesized. Unlike warfarin, they are administered at fixed doses, require neither routine monitoring nor diet, and interact with drugs only in small amounts. The new oral anticoagulants have been approved for certain indications, but the data of performed trials are inapplicable to patients with APS. These medicines are expected to improve quality of life in patients with this condition. 

антифосфолипидный синдромпрофилактика тромбозовпероральные антикоагулянтыantiphospholipid syndromeprevention of thrombosesoral anticoagulantsReferencesНасонов ЕЛ, редактор. Антифосфолипидный синдром. Москва: Литтерра; 2004. 424 с. [Nasonov EL, editor. Antifosfolipidnyi sindrom [Antifosfolipid syndrome]. Moscow: Litterra; 2004. 424 p.].Насонов ЕЛ, редактор. Антифосфолипидный синдром. Москва: Литтерра; 2004. 424 с. [Nasonov EL, editor. Antifosfolipidnyi sindrom [Antifosfolipid syndrome]. Moscow: Litterra; 2004. 424 p.].Решетняк ТМ. Антифосфолипидный синдром: диагноз и принципы терапии. Сonsilium medicum. 2002;(4):408-15 [Reshetnyak TM. Antiphospholipid syndrome: diagnosis and treatment principles. Сonsilium Medicum. 2002;(4):408-15 (In Russ.)].Решетняк ТМ. Антифосфолипидный синдром: диагноз и принципы терапии. Сonsilium medicum. 2002;(4):408-15 [Reshetnyak TM. Antiphospholipid syndrome: diagnosis and treatment principles. Сonsilium Medicum. 2002;(4):408-15 (In Russ.)].Решетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56–71 [Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (A Lecture). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):56-71 (In Russ.)]. doi: 10.14412/1995-4484-2014-56-71Решетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56–71 [Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (A Lecture). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):56-71 (In Russ.)]. doi: 10.14412/1995-4484-2014-56-71Erkan D, Pierangeli SS, editors. Antiphospholipid syndrome: insights and highlights from the 13th International Congress on Antiphospholipid Antibodies. New York: Springer Science+Business Media; 2012. doi: 10.1007/978-1-4614-3194-7_17Erkan D, Pierangeli SS, editors. Antiphospholipid syndrome: insights and highlights from the 13th International Congress on Antiphospholipid Antibodies. New York: Springer Science+Business Media; 2012. doi: 10.1007/978-1-4614-3194-7_17Asherson RA, Cervera R, Piette J-Ch, Shoenfeld Y, editors. The antiphospholipid syndrome II: Autoimmune thrombosis. New York: Elsevier; 2002. P. 3-445.Asherson RA, Cervera R, Piette J-Ch, Shoenfeld Y, editors. The antiphospholipid syndrome II: Autoimmune thrombosis. New York: Elsevier; 2002. P. 3-445.Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.xMiyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.xLevine J, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752-63. doi: 10.1056/NEJMra002974Levine J, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752-63. doi: 10.1056/NEJMra002974Алекберова ЗС, Решетняк ТМ, Раденска СГ и др. Васкулопа- тия у больных системной красной волчанкой с антифосфоли- пидным синдромом. Терапевтический архив. 1995;(5):41-4 [Alekberova ZS, Reshetnyak TM, Radenska SG, et al. Vasculopathy in patients with systemic lupus erythematosus with antiphospholipid syndrome. Terapevticheskii Arkhiv. 1995;(5):41-4 (In Russ.)].Алекберова ЗС, Решетняк ТМ, Раденска СГ и др. Васкулопа- тия у больных системной красной волчанкой с антифосфоли- пидным синдромом. Терапевтический архив. 1995;(5):41-4 [Alekberova ZS, Reshetnyak TM, Radenska SG, et al. Vasculopathy in patients with systemic lupus erythematosus with antiphospholipid syndrome. Terapevticheskii Arkhiv. 1995;(5):41-4 (In Russ.)].Lie JT. Pathology of the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y, eds. The antiphos￾pholipid syndrome. Boca Raton, Fl.: CRC Press; 1996. P. 89-104.Lie JT. Pathology of the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y, eds. The antiphos￾pholipid syndrome. Boca Raton, Fl.: CRC Press; 1996. P. 89-104.Austin S, Cohen H. Antiphospholipid syndrome. Medicine. 2009;34:472-5. doi: 10.1053/j.mpmed.2006.08.012Austin S, Cohen H. Antiphospholipid syndrome. Medicine. 2009;34:472-5. doi: 10.1053/j.mpmed.2006.08.012Середавкина НВ, Решетняк ТМ. IX Европейский форум по антифосфолипидным антителам. Краткий обзор. Научно-пра- ктическая ревматология. 2014;52(1):115-21 [Seredavkina NV, Reshetnyak TM. The IX European forum on antiphospholipid antibodies. A brief review. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):115-21 (In Russ.)]. doi: 10.14412/1995-4484-2014-115-121Середавкина НВ, Решетняк ТМ. IX Европейский форум по антифосфолипидным антителам. Краткий обзор. Научно-пра- ктическая ревматология. 2014;52(1):115-21 [Seredavkina NV, Reshetnyak TM. The IX European forum on antiphospholipid antibodies. A brief review. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):115-21 (In Russ.)]. doi: 10.14412/1995-4484-2014-115-121Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-94S. doi: 10.1378/chest.11-2301 PMID: 22315268Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-94S. doi: 10.1378/chest.11-2301 PMID: 22315268Keeling D, Baglin T, Tait C, et al. British Committee for Standards in Haematology (BCSH) – Guidelines for General Haematology, Haemostasis and Thrombosis. Guidelines on oral anticoagulation with warfarin fourth edition. Br J Haematol. 2011;154:311-24. doi: 10.1111/j.1365-2141.2011.08753.x. Epub 2011 Jun 14. PMID: 21671894Keeling D, Baglin T, Tait C, et al. British Committee for Standards in Haematology (BCSH) – Guidelines for General Haematology, Haemostasis and Thrombosis. Guidelines on oral anticoagulation with warfarin fourth edition. Br J Haematol. 2011;154:311-24. doi: 10.1111/j.1365-2141.2011.08753.x. Epub 2011 Jun 14. PMID: 21671894Ruiz-Irastorza G, Crowther M, Branch W, Khamashta M. Antiphospholipid syndrome. Lancet. 2010;376:1498-509. doi: 10.1016/S0140-6736(10)60709-X. Epub 2010 Sep 6. PMID: 20822807Ruiz-Irastorza G, Crowther M, Branch W, Khamashta M. Antiphospholipid syndrome. Lancet. 2010;376:1498-509. doi: 10.1016/S0140-6736(10)60709-X. Epub 2010 Sep 6. PMID: 20822807Arachchillage DJ, Cohen H. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep. 2013 Jun;15(6):331. doi: 10.1007/s11926-013-0331-5. PMID: 23649961Arachchillage DJ, Cohen H. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep. 2013 Jun;15(6):331. doi: 10.1007/s11926-013-0331-5. PMID: 23649961Boehringer Ingelheim International GmBH, 21/09/2012. Available from: www.emc.medicines.org.ukBoehringer Ingelheim International GmBH, 21/09/2012. Available from: www.emc.medicines.org.ukXarelto 10 mg film-coated tablets. Summary of product characteristics (SPC), EU. Bayer HealthCare AG. Date of first authorisation/ renewal of authorisation: 30/09/08. Date of revision 12/2011. Available from: www.emc.medicines.org.ukXarelto 10 mg film-coated tablets. Summary of product characteristics (SPC), EU. Bayer HealthCare AG. Date of first authorisation/ renewal of authorisation: 30/09/08. Date of revision 12/2011. Available from: www.emc.medicines.org.ukEriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41-57. doi: 10.1146/annurev-med- 062209-095159. PMID: 21226611Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41-57. doi: 10.1146/annurev-med- 062209-095159. PMID: 21226611Frost C, Yu Z, Nepal S, et al. Apixaban, an oral direct, factor Xa inhibitor: multiple ascending-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost. 2007;5 Suppl 2:P-M-664.Frost C, Yu Z, Nepal S, et al. Apixaban, an oral direct, factor Xa inhibitor: multiple ascending-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost. 2007;5 Suppl 2:P-M-664.Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159:331-9. doi: 10.1016/j.ahj.2009.07.035. PMID: 20211292Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159:331-9. doi: 10.1016/j.ahj.2009.07.035. PMID: 20211292Patel M; for the ROCKET AF Study Investigators. Rivaroxaban – Once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340-7. doi: 10.1016/j.ahj.2009.11.025Patel M; for the ROCKET AF Study Investigators. Rivaroxaban – Once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340-7. doi: 10.1016/j.ahj.2009.11.025Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011 Oct;72(4):581-92. doi: 10.1111/j.1365- 2125.2011.03916.x. PMID:21241354Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011 Oct;72(4):581-92. doi: 10.1111/j.1365- 2125.2011.03916.x. PMID:21241354Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G, et al. Dabigatran, rivaroxaban, orapixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systemic review and meta￾analysis of subgroups. Thrombosis. 2013;2013:640723. doi: 10.1155/2013/640723. Epub 2013 Dec 22. PMID: 24455237Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G, et al. Dabigatran, rivaroxaban, orapixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systemic review and meta￾analysis of subgroups. Thrombosis. 2013;2013:640723. doi: 10.1155/2013/640723. Epub 2013 Dec 22. PMID: 24455237Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. PMID: 19717844Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. PMID: 19717844Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor Ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet. 2003 Nov 22;362(9397):1691-8. PMID:14643116Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor Ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet. 2003 Nov 22;362(9397):1691-8. PMID:14643116Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005 Feb 9;293(6):690-8. PMID: 15701910Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005 Feb 9;293(6):690-8. PMID: 15701910Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med. 2013 Jul;80(7):443-51. doi: 10.3949/ccjm.80a.13025. PMID: 23821689Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med. 2013 Jul;80(7):443-51. doi: 10.3949/ccjm.80a.13025. PMID: 23821689Erikkson BI, Dahl OE, Rosencher N, et al; RE-MODEL Study Group. Oral dabigatranetexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the Re-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-85. doi: 10.1111/j.1538-7836.2007.02748.xErikkson BI, Dahl OE, Rosencher N, et al; RE-MODEL Study Group. Oral dabigatranetexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the Re-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-85. doi: 10.1111/j.1538-7836.2007.02748.xSchulman S, Kakkar AK, Goldhaber SZ, et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129(7):764-72. doi: 10.1161/CIRCULATIONA￾HA.113.004450. Epub 2013 Dec 16. PMID: 24344086Schulman S, Kakkar AK, Goldhaber SZ, et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129(7):764-72. doi: 10.1161/CIRCULATIONA￾HA.113.004450. Epub 2013 Dec 16. PMID: 24344086NICE technology appraisal guidance 249. Dabigatranetexilate for the prevention of stroke and systemic embolism in atrial fibrilla￾tion.March 2012. Available from: www.nice.org.uk/TA249NICE technology appraisal guidance 249. Dabigatranetexilate for the prevention of stroke and systemic embolism in atrial fibrilla￾tion.March 2012. Available from: www.nice.org.uk/TA249Approval Drugs by FDA. Available from. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugsApproval Drugs by FDA. Available from. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugsGuidance in development. Pulmonary embolism (acute treatment, VTE prevention) – rivaroxaban [ID569]. Available from: www.nice.org.ukGuidance in development. Pulmonary embolism (acute treatment, VTE prevention) – rivaroxaban [ID569]. Available from: www.nice.org.ukDanowski A, de Azevedo MN, de Souza Papi JA, et al. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009 Jun;36(6):1195-9. doi: 10.3899/jrheum.081194. Epub 2009 May 15. PMID: 19447935Danowski A, de Azevedo MN, de Souza Papi JA, et al. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009 Jun;36(6):1195-9. doi: 10.3899/jrheum.081194. Epub 2009 May 15. PMID: 19447935Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome.Rheumatology (Oxford). 2002 Aug;41(8):924-9. PMID: 12154210Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome.Rheumatology (Oxford). 2002 Aug;41(8):924-9. PMID: 12154210Ruffatti A, Del Ross T, Ciprian M, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis. 2009 Mar;68(3):397-9. doi: 10.1136/ard.2008.096669. Epub 2008 Sep 23. PMID: 18812393Ruffatti A, Del Ross T, Ciprian M, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis. 2009 Mar;68(3):397-9. doi: 10.1136/ard.2008.096669. Epub 2008 Sep 23. PMID: 18812393Gage BF. Can we rely on Re-LY? N Engl J Med. 2009 Sep 17;361(12):1200-2. doi: 10.1056/NEJMe0906886. Epub 2009 Aug 30. PMID: 19717843Gage BF. Can we rely on Re-LY? N Engl J Med. 2009 Sep 17;361(12):1200-2. doi: 10.1056/NEJMe0906886. Epub 2009 Aug 30. PMID: 19717843Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010 Nov 4;363(19):1875- 6. doi: 10.1056/NEJMc1007378. PMID: 21047252Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010 Nov 4;363(19):1875- 6. doi: 10.1056/NEJMc1007378. PMID: 21047252Turpie AG, Lassen MR, Davidson BL, et al; RECORD 4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement (RECORD 4): a randomised trial. Lancet. 2009;373:1673-80. doi: 10.1016/S0140- 6736(09)60734-0. Epub 2009 May 4. PMID: 19411100Turpie AG, Lassen MR, Davidson BL, et al; RECORD 4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement (RECORD 4): a randomised trial. Lancet. 2009;373:1673-80. doi: 10.1016/S0140- 6736(09)60734-0. Epub 2009 May 4. PMID: 19411100Patel MR, Mahaffey KW, Gar J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (and supplementary appendix). N Engl J Med. 2011;365:883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10. PMID: 21830957Patel MR, Mahaffey KW, Gar J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (and supplementary appendix). N Engl J Med. 2011;365:883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10. PMID: 21830957NICE technology appraisal guidance 256. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. May 2012. Available from: www.nice.org.uk/TA256NICE technology appraisal guidance 256. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. May 2012. Available from: www.nice.org.uk/TA256EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism (and supplementary appendix). N Engl J Med. 2010;363:2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3. PMID: 21128814EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism (and supplementary appendix). N Engl J Med. 2010;363:2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3. PMID: 21128814Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27. PMID: 21870978Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27. PMID: 21870978Eliquis 2.5 mg film-coated tablets film-coated tablets Summary of Product Characteristics (SPC) last updated on the eMC: 03/12/2012. Available from: www.emc.medicines.org.ukEliquis 2.5 mg film-coated tablets film-coated tablets Summary of Product Characteristics (SPC) last updated on the eMC: 03/12/2012. Available from: www.emc.medicines.org.ukGuidance in development. Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) – apixaban [ID500]. Available from: www.nice.org.ukGuidance in development. Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) – apixaban [ID500]. Available from: www.nice.org.ukReference ID: 3212129. Available from: www.accessdata.fda.gov/ scripts/cder/drugsatfdaReference ID: 3212129. Available from: www.accessdata.fda.gov/ scripts/cder/drugsatfdaNICE technology appraisal guidance 261. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. July 2012. Available from: www.nice.org.uk/TA 261NICE technology appraisal guidance 261. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. July 2012. Available from: www.nice.org.uk/TA 261Guidance in development. Dabigatranetexilate for the treatment of acute venous thromboembolic events (ID108). Available from: www.nice.org.ukGuidance in development. Dabigatranetexilate for the treatment of acute venous thromboembolic events (ID108). Available from: www.nice.org.ukXarelto 20 mg film-coated tablets. Summary of product characteristics (SPC), EU. Bayer Health Care AG. Last updated on the eMC: 04/ 12/2012. Available from: www.emc.medicines.org.ukXarelto 20 mg film-coated tablets. Summary of product characteristics (SPC), EU. Bayer Health Care AG. Last updated on the eMC: 04/ 12/2012. Available from: www.emc.medicines.org.ukEINSTEIN-PE Investigators, Bü ller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26. PMID: 22449293EINSTEIN-PE Investigators, Bü ller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26. PMID: 22449293Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;36(6):594-604. doi: 10.1056/NEJMoa0810773. PMID: 19657123Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;36(6):594-604. doi: 10.1056/NEJMoa0810773. PMID: 19657123Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807-15. doi: 10.1016/S0140-6736(09)62125-5. PMID: 20206776Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807-15. doi: 10.1016/S0140-6736(09)62125-5. PMID: 20206776Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement (ADVANCE-3). N Engl J Med. 2010;363(26):2487-98. doi: 10.1056/NEJMoa1006885. PMID: 21175312Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement (ADVANCE-3). N Engl J Med. 2010;363(26):2487-98. doi: 10.1056/NEJMoa1006885. PMID: 21175312NICE technology appraisal guidance 245.Venous thromboembolism – apixaban (hip and knee surgery). January 2012. Available from: www.nice.org.uk/TA 245NICE technology appraisal guidance 245.Venous thromboembolism – apixaban (hip and knee surgery). January 2012. Available from: www.nice.org.uk/TA 245Schulman S, Kearon C, Kakkar, et al; for the Re-COVER Study Group. Dabigatran versus warfarin for the treatment of acute venous thromboembolism. N Engl Med. 2009;361:2341-52. doi: 10.1056/NEJMoa0906598. PMID: 19966341Schulman S, Kearon C, Kakkar, et al; for the Re-COVER Study Group. Dabigatran versus warfarin for the treatment of acute venous thromboembolism. N Engl Med. 2009;361:2341-52. doi: 10.1056/NEJMoa0906598. PMID: 19966341Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8. PMID: 23216615Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8. PMID: 23216615Development status of rivaroxaban, apixabanedoxaban and dabigatran. Available from: www.clinicaltrials.govDevelopment status of rivaroxaban, apixabanedoxaban and dabigatran. Available from: www.clinicaltrials.govFareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. Ann Rev Pharmacol Toxicol. 2012;52:79-99. doi: 10.1146/annurev-pharmtox-010611-134633. Epub 2011 Aug 5. PMID: 21819239Fareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. Ann Rev Pharmacol Toxicol. 2012;52:79-99. doi: 10.1146/annurev-pharmtox-010611-134633. Epub 2011 Aug 5. PMID: 21819239Pengo V, Crippa L, Falanga A, et al. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost. 2012;10(10):1979- 87. doi: 10.1111/j.1538-7836.2012.04866.x. PMID: 22827490Pengo V, Crippa L, Falanga A, et al. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost. 2012;10(10):1979- 87. doi: 10.1111/j.1538-7836.2012.04866.x. PMID: 22827490Buller HR. Once-daily oral rivaroxaban versus placebo in the longterm prevention of recurrent symptomatic venous thromboembolism, the Einstein-Extension Study. Late Breaking Abstracts LBA-2. 51st ASH Annual Meeting and Exposition; 2009.Buller HR. Once-daily oral rivaroxaban versus placebo in the longterm prevention of recurrent symptomatic venous thromboembolism, the Einstein-Extension Study. Late Breaking Abstracts LBA-2. 51st ASH Annual Meeting and Exposition; 2009.Harder S. Renal profiles of anticoagulants. J Clin Pharmacol. 2012;52(7):964-75. doi: 10.1177/0091270011409231. Epub 2011 May 24. PMID: 21610202Harder S. Renal profiles of anticoagulants. J Clin Pharmacol. 2012;52(7):964-75. doi: 10.1177/0091270011409231. Epub 2011 May 24. PMID: 21610202Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus. 2010;19:486-91. doi: 10.1177/0961203310361355. PMID: 20353992Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus. 2010;19:486-91. doi: 10.1177/0961203310361355. PMID: 20353992Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidence from British Committee for Standards in Haematology. Br J Haematol. 2012;159(4):427-9. doi: 10.1111/bjh.12052. PMID: 22970737Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidence from British Committee for Standards in Haematology. Br J Haematol. 2012;159(4):427-9. doi: 10.1111/bjh.12052. PMID: 22970737Ryn J, Stangier J, Haertter S, et al. Dabigatranetexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010 Jun;103(6):1116-27. doi: 10.1160/TH09-11-0758. Epub 2010 Mar 29. PMID: 20352166Ryn J, Stangier J, Haertter S, et al. Dabigatranetexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010 Jun;103(6):1116-27. doi: 10.1160/TH09-11-0758. Epub 2010 Mar 29. PMID: 20352166Pradaxa®. Summary of Product Characteristics, 2011. Boehringer Ingelheim.Pradaxa®. Summary of Product Characteristics, 2011. Boehringer Ingelheim.Liesenfeld KH, Schafer HG, Troconiz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006 Nov;62(5):527-37. doi: 10.1111/j.1365- 2125.2006.02667.x. PMID: 17061960Liesenfeld KH, Schafer HG, Troconiz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006 Nov;62(5):527-37. doi: 10.1111/j.1365- 2125.2006.02667.x. PMID: 17061960Van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med. 2012 Apr;125(4):417-20. doi: 10.1016/j.amjmed.2011.10.017. Epub 2012 Feb 3. PMID: 22306274Van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med. 2012 Apr;125(4):417-20. doi: 10.1016/j.amjmed.2011.10.017. Epub 2012 Feb 3. PMID: 22306274Agarwal MB, Verma S, Mahapatra M, et al. Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants. Indian J Hematol Blood Transfus. 2012 Sep;28(3):129-43. doi: 10.1007/s12288-012-0167- 6. Epub 2012 Jul 28. PMID: 23997448Agarwal MB, Verma S, Mahapatra M, et al. Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants. Indian J Hematol Blood Transfus. 2012 Sep;28(3):129-43. doi: 10.1007/s12288-012-0167- 6. Epub 2012 Jul 28. PMID: 23997448Antovic JP, Skeppholm M, Eintrei J, et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol. 2013 Nov;69(11):1875-81. doi: 10.1007/s00228-013-1550-4. Epub 2013 Jun 20. PMID: 23784008Antovic JP, Skeppholm M, Eintrei J, et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol. 2013 Nov;69(11):1875-81. doi: 10.1007/s00228-013-1550-4. Epub 2013 Jun 20. PMID: 23784008Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012 Mar;23(2):138-43. doi: 0.1097/MBC.0b013e32834f1b0c. PMID: 22227958Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012 Mar;23(2):138-43. doi: 0.1097/MBC.0b013e32834f1b0c. PMID: 22227958Martinuzzo ME, Barrera LH, D’Adamo MA, et al. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol. 2014;36(2):144-50. doi: 10.1111/ijlh.12138. Epub 2013 Sep 6. PMID: 24034808Martinuzzo ME, Barrera LH, D’Adamo MA, et al. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol. 2014;36(2):144-50. doi: 10.1111/ijlh.12138. Epub 2013 Sep 6. PMID: 24034808Makris M, Joost J, van Veen JJ, et al. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haem. 2012;160:35-46. doi: 10.1111/bjh.12107. Epub 2012 Nov 1. PMID: 23116425Makris M, Joost J, van Veen JJ, et al. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haem. 2012;160:35-46. doi: 10.1111/bjh.12107. Epub 2012 Nov 1. PMID: 23116425Turpie AGG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor. Thromb Haemost. 2012;108:876-86. doi: 10.1160/TH12- 03-0209. Epub 2012 Sep 26. PMID: 23014816Turpie AGG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor. Thromb Haemost. 2012;108:876-86. doi: 10.1160/TH12- 03-0209. Epub 2012 Sep 26. PMID: 23014816Spyropoulos ACD, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120(15):2954-62. doi: 10.1182/blood-2012-06-415943. Epub 2012 Aug 28. PMID: 22932800Spyropoulos ACD, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120(15):2954-62. doi: 10.1182/blood-2012-06-415943. Epub 2012 Aug 28. PMID: 22932800Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016-23. doi: 10.1182/blood-2011-10- 378950. Epub 2012 Feb 1. PMID: 22302737Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016-23. doi: 10.1182/blood-2011-10- 378950. Epub 2012 Feb 1. PMID: 22302737Llau JV, Ferrandis R. New anticoagulants and regional anesthesia. Curr Opin Anaesthesiol. 2009;22:661-6. doi: 10.1097/ACO.0b013e32832eb8ab. PMID: 19568169Llau JV, Ferrandis R. New anticoagulants and regional anesthesia. Curr Opin Anaesthesiol. 2009;22:661-6. doi: 10.1097/ACO.0b013e32832eb8ab. PMID: 19568169

The authors declare that there are no conflicts of interest present.